EUVIMEDEUVIMED entdecken
Crossref

Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population

Sarah Bouhmouch, Béatrice Dubern, Catherine Terraz, Patrick Tounian

Archives de Pédiatrie · 2026

DOI: 10.1016/j.arcped.2026.105545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives de Pédiatrie, 2026. Verfasst von Sarah Bouhmouch und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, Paris, France. Electronic address: sarah.bouhmouch@outlook.com. Hauptthemen laut MEDLINE: Liraglutide, Glucagon-Like Peptide 1, Pediatric Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adolescent obesity is a chronic condition. The pathophysiology of this complex disease involves genetic mechanisms that influence appetite regulation via the hypothalamus, with environmental factors acting as triggers or aggravating factors. METHODS: Curative treatment relies on a restrictive diet, which is difficult to maintain long term. In this context, pharmacotherapy, particularly GLP-1 analogues, has proven effective in adults and is considered a therapeutic alternative for adolescents. However, their efficacy and tolerance in obese adolescents without diabetes remain poorly studied, particularly in France. RESULTS: This study evaluated the efficacy and tolerance of liraglutide in 20 obese, non-diabetic adolescents in France. Overall efficacy was lower than expected and lower than in previous publications. Eleven patients (55%) lost weight, but only 3 (15%) lost >5%. However, 7 of the 12 patients (58%) whose body composition was measured lost at least 5% of their fat mass. Sixty-five percent of patients experienced gastrointestinal side effects (nausea, vomiting, diarrhea). These side effects led to discontinuation of treatment in 20% of patients. CONCLUSION: Although our study is limited by its small sample size and single-center design, it confirms the poor efficacy of liraglutide in obese adolescents. However, drug treatments remain a promising therapeutic option for adolescent obesity. Future development will likely enable more effective management of obese adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideGlucagon-Like Peptide 1Pediatric ObesityHypoglycemic AgentsHumansAdolescentFranceFemaleMaleTreatment OutcomeChildWeight Loss

Stichwörter der Autor:innen

Adolescent obesityBMIBody compositionChildhood obesityGLP-1 analogues

Substanzen

LiraglutideGlucagon-Like Peptide 1Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, Paris, France. Electronic address: sarah.bouhmouch@outlook.com.
  • Department of Pediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, Paris, France; Sorbonne University, Paris, France.
  • Department of Pediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, Paris, France.

Zitieren

APA

Bouhmouch, S., Dubern, B., Terraz, C., & Tounian, P. (2026). Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population. Archives de Pédiatrie. https://doi.org/10.1016/j.arcped.2026.105545

Vancouver

Bouhmouch S, Dubern B, Terraz C, Tounian P. Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population. Archives de Pédiatrie. 2026. doi:10.1016/j.arcped.2026.105545

BibTeX
@article{Bouhmouch2026,
  author = {Bouhmouch, Sarah and Dubern, Béatrice and Terraz, Catherine and Tounian, Patrick},
  title = {Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population},
  journal = {Archives de Pédiatrie},
  year = {2026},
  doi = {10.1016/j.arcped.2026.105545}
}
Kostenlos starten →